Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 34 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 34 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Caspase-3 activity in pregnant rat spleen and lymph nodes after treatment with cycloheximide and the development of malignant breast tumor in experimental animals: case report
Authors H. Frangou1, E. Nikoloussis2, N. Massouridou1, T. Vavilis1 and E.-N. Emmanouil2

1. Deparment of General Biology and 2. Laboratory of Histology – Embryology & Anthropology, Medical School, Aristotle University of Thessaloniki, Greece

Citation Frangou, H., Nikoloussis, E., Massouridou, N., Vavilis, T., Emmanouil, E.-N.: Caspase-3 activity in pregnant rat spleen and lymph nodes after treatment with cycloheximide and the development of malignant breast tumor in experimental animals: case report, Epitheorese Klin. Farmakol. Farmakokinet. 22(2): 141-144 (2008)
Publication Date 23-25 May 2008
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)

pharmakonpress[at]pharmakonpress[.]gr

Keywords Cycloheximide, caspase-3, spleen, lymph nodes, malignant breast tumor.
Other Terms Review article
Summary Cycloheximide (CHX) was found to induce teratogenesis and apoptosis in some cell types, tissues and organs. Although toxic, CHX is used as a pesticide/infecticide drug for plants and fruits. During an extended research protocole we have identified the development of a malignant breast tumor in a rat treated with CHX. Therefore we have tried to investigate the mechanism of action of CHX determining caspase-3 activity in subcellular fractions of spleen and lymph nodes related to the tumor of the rat which presented this tumor during and after gestational period. Caspase-3 activity was determined in crude, nuclear, and cytosolic plus ribosomal fraction of spleen and lymph nodes by a colorimetric assay (kit, Sigma). Our results indicate enhanced caspase-3 activity in subcellular fractions of the above tissues. From our findings we support the theory that CHX may induce apoptosis by enhancing caspase-3 activity in pregnant rat spleen and lymph nodes during malignant breast tumor development.
References 1. Jacobson M.D., Weil M., Raff M.C.: Programmed cell death in animal development. Cell 88: 347-354 (1997)

2. Wyllie A.H., Kerr J.E., Currie A.R.: Cell death: the significance of apoptosis. Int. Rev. Cytol.  68: 251-306 (1980)

3. Cohen G.M.: Caspases: the executioners of apoptosis. Biochem. J. 326: 1-16 (1997)

4. Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G.: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273: 9357-9360 (1988)

5. Sakahira H., Enari M., Nagata S.: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99 (1998)

6. Nickolson D.W., Ali A., et al.: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43 (1995)

7. Shiokawa D., Ohyama H., Yamada T., Takahashi K., Tanuma S.: Identification of an endonuclease responsible for apoptosis in rat thymocytes. Eur. J. Biochem. 226: 23-30 (1994)

8. Bajic V., Milicevic Z., Spremo-Potparevic B.: A negative adaptive response is expressed in peripheral blood lymphocytes that are exposed to mitomycin C and cycloheximide. J. BUON  10(1): 111-117 (2005)

9. Satav J.G., Katyare S.S., Fatterparker P., Sreenivasan A.: Study of protein synthesis in rat liver mitochondria use of cycloheximide. Eur. J. Biochem. 73(1): 187-193 (1977)

10. Mullauer L., Mosberger I., Grusch M., Rudas M., Chott A.: Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J. Pathol. 190: 20-30 (2000). Comment in: J. Pathol. 191: 468-470 (2000)

11. Tang D., Lahti J.M., Grenet J., Kidd V.J.: Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism J. Biol. Chem. 274: 7245-7252 (1999)

12. Emmanouil-Nikoloussi E.-N., Frangou-Massourides H.: Cycloheximide a protein synthesis inhibitor with teratogenic, embryotoxic and carcinogenetic expression. Aristotle University Medical Journal 34(1): 35-38 (2007)

13. Emmanouil-Nicoloussi E.-N., Frangou H., Nikolousis E., Manthou M.-E., Papamitsou Th., Goula Ch., Massouridou S., Likartsis Ch., Lazaridis Ch, Manthos A.: Enormous rat breast tumor development after cycloheximide treatment during pregnancy. Histochemical and immunohistochemical A, and B estrogen receptor identification. Hell. Med. 73: 335-341 (2007)

14. Nordlie R.C., Lardy H.A.: Subcellular distribution of rat liver PPiase activity. Biochim. Biophys. Acta 50: 189-191 (1961)

15. Bradford M.: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72: 248-254 (1976)

16. Bearden J.C.: Quantitation of submicrogram quantities of protein by an improved protein-dye binding assay. Biochim. Biophys. Acta 533: 525-529 (1978)  

17. Kistler A.: Teratogenesis of retinoic acid in rats: susceptible stages and suppression of retinoic acid-induced limb malformations by cycloheximide. Teratology 23(1): 25-31 (1981)

18. Courchesne C.L., Bantle J.A.: Analysis of the activity of DNA, RNA, and protein synthesis inhibitors on Xenopus embryo development. Teratog. Carcinog. Mutagen 5: 177-193 (1985)

19. Tsuchida T., Kato T., Yamada A., Kawamoto K.: Cycloheximide induces apoptosis of astrocytes. Pathol. Int. 52: 181-185 (2002)

20. Yu A.C, Yung H.W., Hui M.H., Lau L.T., Chen X.Q., Collins R.A.: Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and lce gene expression in astrocytes under in vitro ischemia. J. Neurosci. Res. 74: 318-325 (2003)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

 

 

Bookmark the permalink.

Comments are closed.